Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Safety and Tolerability Study of NWRD08 in HPV-16 and/or HPV-18 Related Cervical High-grade Squamous Intraepithelial Lesion (HSIL) Patients

NCT06276101 is registered in ClinicalTrials.gov with Newish Technology (Beijing) Co., Ltd. as lead sponsor.

NCT NCT06276101
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06276101 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Safety and Tolerability Study of NWRD08 in HPV-16 and/or HPV-18 Related Cervical High-grade Squamous Intraepithelial Lesion (HSIL) Patients
Lead sponsor
Newish Technology (Beijing) Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
May 7, 2024
Completion date
December 30, 2025
Enrollment
9 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

high-grade squamous intraepithelial lesion (hsil)